Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

73.06 -1.17 (-1.58%)
Delayed Quote Updated: 1:23 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,093
Open 73.47
Bid (Size) 72.78 (100)
Ask (Size) 73.82 (100)
Prev. Close 74.23
Today's Range 73.06 - 75.08
52wk Range 50.07 - 124.82
Shares Outstanding 14,157,941
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Monopar Therapeutics Inc.
Via GlobeNewswire

Performance

52-Week Range 41.5% below 52-week high
73.06
50.0752W Low 124.8252W High
1 Week 2.5% below 1-week high
68.811W Low 74.891W High

Monopar Therapeutics Inc. - Common Stock (MNPR) traded between $50.07 and $124.82 over the past 52 weeks and last traded at $73.06, 41.5% below its 52-week high. Over the past week it ranged between $68.81 and $74.89.

Past 12 Months
-0.1%
-23.7%
-35.7%
+38.6%
+10.7%
-5.3%
1W -$0.04
1M -$22.66
3M -$40.51
6M +$20.35
YTD +$7.05
1Y -$4.09

MNPR was -5.3% over the past year, +38.6% over six months, +10.7% year to date, -0.1% in the last week.

12 Months vs Market
MNPR
-5.3%
DIA
+12.7%
SPY
+15.3%
QQQ
+18.9%
IWM
+11.6%

Over the past 12 months MNPR returned -5.3% versus DIA (Dow) +12.7%, SPY (S&P 500) +15.3%, QQQ (Nasdaq 100) +18.9% and IWM (Russell 2000) +11.6%.

Volume & Liquidity 0.15× 3-mo avg
Today 31,093 3-mo avg 201.8K
1W
118.7K
1M
154.1K
3M
201.8K
6M
189.4K
YTD
207.6K
1Y
204.7K

MNPR most recently traded 31,093 shares against a 3-month average daily volume of 201.8K.

More News

Read More
News headline image
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
Via Benzinga
News headline image
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
News headline image
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗
Via Investor's Business Daily
News headline image
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monopar Therapeutics Inc. - Common Stock publicly traded?
Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Monopar Therapeutics Inc. - Common Stock trade on?
Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?
The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market
What is the current price of Monopar Therapeutics Inc. - Common Stock?
The current price of Monopar Therapeutics Inc. - Common Stock is 73.06
When was Monopar Therapeutics Inc. - Common Stock last traded?
The last trade of Monopar Therapeutics Inc. - Common Stock was at 10/21/26 01:23 PM ET
What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?
The market capitalization of Monopar Therapeutics Inc. - Common Stock is 1.03B
How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?
Monopar Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.